The small molecule inhibitor of JMJD3/UTX was recently suggested as a novel therapy for pediatric brainstem glioma [14] and T-cell acute lymphoblastic leukemia [13]. This evidence concerns the gene KDM6A and T-cell acute lymphoblastic leukemia.